Welcome to our dedicated page for Neuraxis SEC filings (Ticker: NRXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeurAxis, Inc. filings document the regulatory, financial, governance, and capital-structure disclosures of a medical technology company built around PENFS neuromodulation. Its 8-K reports cover preliminary operating results, FDA 510(k) clearance for PENFS indications, at-the-market common stock offering arrangements under a Form S-3 registration statement, related prospectus supplements and legal opinions, and material agreements involving licensed neuromodulation assets.
NeurAxis proxy materials disclose annual meeting matters, director elections, auditor ratification, equity incentive plan amendments, an employee stock purchase plan, and voting rights involving common stock and Series B Preferred Stock. The filing record also documents corporate governance, stock-based compensation plans, material contract changes, and risk-bearing financing mechanisms tied to its commercialization strategy.
Neuraxis, INC (NRXS) reported insider equity compensation activity for officer Thomas Joeseph Carrico on 2026-08-24. Stock options for 306,236 shares were canceled and converted into an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, following approval by the board and stockholders. These RSUs vested immediately upon grant.
In a related event, 306,236 RSUs were granted and vested, and the company stated that, in connection with this vesting, 112,558 shares were withheld to satisfy income tax withholding and remittance obligations. After these events, 193,678 shares of common stock were acquired for the reporting person, bringing his directly held common stock position to 199,345 shares.
Neuraxis, Inc. (NRXS) reported that officer Adrian Miranda, CMO and SVP Science & Tech, had existing stock options canceled and replaced with restricted stock units under the company’s 2022 Omnibus Securities and Incentive Plan. 337,204 stock options were canceled in exchange for 337,204 RSUs, which vested immediately upon grant and converted into common stock. In connection with this vesting, 138,098 shares were withheld by Neuraxis to satisfy income tax obligations, and 199,106 common shares were issued and are now held directly by Miranda.
Neuraxis, INC (NRXS) reported equity compensation changes for Chief Executive Officer Brian Allen Carrico. On 2026-08-24, 320,000 stock options previously issued under a prior plan were canceled and converted into an equivalent 320,000 RSUs under the 2022 Omnibus Plan, with the RSUs vesting immediately upon grant. In connection with vesting, 120,812 shares of common stock were withheld to satisfy income tax obligations, and the remaining 199,188 shares were issued, bringing Carrico’s directly held common stock to 227,336 shares. These transactions were not reported as occurring under a Rule 10b5-1 trading plan.
Neuraxis, Inc. (NRXS) reports that a previously approved Stock Option Exchange became effective on July 24, 2026. Stockholders had approved cancelling 1,319,394 outstanding stock options under a prior plan and issuing an equivalent number of restricted stock units (RSUs) under the 2022 Omnibus Securities and Incentive Plan on a one-for-one basis. As a result, CEO Brian Carrico, CMO Adrian Miranda, and Chief Regulatory Officer Thomas Carrico received 199,188, 199,106, and 193,678 RSUs, all vesting immediately.
On August 13, 2026, after Compensation Committee approval, Neuraxis granted additional RSUs under the 2022 Plan: 193,329 to Brian Carrico, 141,479 to CFO Timothy Henrichs, 133,341 to Adrian Miranda, and 135,906 to Thomas Carrico, vesting in three equal annual installments over three years. The Compensation Committee also approved one-time equity awards totaling 127,120 shares of common stock to independent directors in recognition of prior Board service, following a review by an independent compensation consultant that found historical director compensation below market levels.
Watkins Bradley Mitchell reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, Inc. (NRXS) reported that director Bradley Mitchell Watkins received an equity compensation grant of 26,073 shares of common stock on 2026-08-13. The shares were issued as compensation for services as an independent director, not as an open-market purchase, bringing his directly held stake to 72,408 shares.
Miranda Adrian reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, Inc. reported an equity compensation grant to executive Adrian Miranda, its CMO and SVP Science & Tech. Miranda received 133,341 RSUs, each representing one share of common stock, as compensation under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan. The RSUs vest in three equal annual installments over three years, and Miranda now directly holds 133,341 RSUs tied to common shares.
Keyser Jane Elizabeth reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, Inc. director Jane Elizabeth Keyser reported an award of 26,073 shares of Common Stock on 2026-08-13 at a reported value of $6.28 per share. The shares were issued as compensation for her services as an independent director. Following this grant, her direct holdings total 72,408 shares of Neuraxis common stock.
Henrichs Timothy Robert reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, Inc. (NRXS) reported an equity compensation grant to its Chief Financial Officer, Timothy Robert Henrichs. He received 141,479 RSUs, representing the right to receive an equal number of shares of common stock. The award was valued at $6.28 per unit for reporting purposes and was granted under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over three years, and the filing shows Henrichs holding 141,479 shares/units directly following this award.
Ferge Kristin A reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, INC director Kristin A. Ferge received a grant of 31,134 shares of common stock on 2026-08-13 at a reported value of $6.28 per share. The shares were issued as compensation for services as an independent director, bringing her directly held common stock position to 67,072 shares after the award.
Carrico Thomas Joeseph reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, Inc. reported that officer Thomas Joeseph Carrico received a grant of 135,906 RSUs of common stock as compensation under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan. The RSUs, valued at $6.28 per unit, vest in three equal annual installments over a three-year period, and Carrico now directly holds 135,906 RSUs.